Lico, Maura Q.
HRN: 16-64-02 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/12/2023
CEFTAZIDIME 1GM (VIAL)
12/12/2023
12/18/2023
IV
1gm
Q8
Cap Mr
Waiting Final Action
Indication: Empiric Then Culture-directed Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes